FRAXIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H18O10
Molecular Weight	370.3081
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(O)C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)=C3OC(=O)C=CC3=C1

InChI

InChIKey=CRSFLLTWRCYNNX-QBNNUVSCSA-N

InChI=1S/C16H18O10/c1-23-7-4-6-2-3-9(18)25-14(6)15(11(7)20)26-16-13(22)12(21)10(19)8(5-17)24-16/h2-4,8,10,12-13,16-17,19-22H,5H2,1H3/t8-,10-,12+,13-,16+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16264268 | https://www.ncbi.nlm.nih.gov/pubmed/28922728 | https://www.ncbi.nlm.nih.gov/pubmed/15930756

Cortex fraxini, a famous Chinese herbal folk medicine, is used for the clinical treatment of hyperuricemia, arthritis, diarrhea, liver-protective. and bacillary dysentery. Fraxin, a main active component isolated from Cortex fraxini, possesses a variety of bioactivities such as anti-inflammatory, antioxidant, analgesic, antimicrobial, antiviral, immunomodulatory, anti-hyperuricemia and diuresis. And a recent study indicated that fraxin showed potent hepatoprotective effects in vitro and in vivo, presumably through reducing Oxidative Stress. Fraxin protects cells from oxidative stress.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Oxidative Stress 160 Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16264268 \| https://www.ncbi.nlm.nih.gov/pubmed/28383514	Inhibitor 8297
Carbonic anhydrase IX 35 Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22892213	Inhibitor 8297	0.61 µM [Ki]
Carbonic anhydrase VII 34 Target ID: CHEMBL2326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22892213	Inhibitor 8297	4.32 µM [Ki]
Carbonic anhydrase I 62 Target ID: CHEMBL261 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22892213	Inhibitor 8297	4.86 µM [Ki]
Carbonic anhydrase XII 30 Target ID: CHEMBL3242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22892213	Inhibitor 8297	7.7 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Acute liver injury 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28922728 https://www.ncbi.nlm.nih.gov/pubmed/28383514	Primary		Preclinical	Unknown Approved Use Unknown
Hyperuricemia 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21620826	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

In mice model, pretreatment with fraxin (10, 20 or 40mg/kg) along with CCl4 significantly alleviated liver damage as indicated by the decreased levels of liver index, liver marker enzymes, lipid peroxidation, inflammatory mediators, increased levels of the antioxidant enzymatic and non-enzymatic defense parameters, and improved hepatic histopathology changes.

Route of Administration: Oral

In Vitro Use Guide

Fraxin showed free radical scavenging effect at high concentration (0.5 mM) and cell protective effect against H2O2-mediated oxidative stress.

Name

Type

Language

FRAXIN

Common Name

English

FRAXOSIDE

Common Name

English

7,8-DIHYDROXY-6-METHOXYCOUMARIN 8-.BETA.-D-GLUCOPYRANOSIDE

Common Name

English

2H-1-BENZOPYRAN-2-ONE, 8-(.BETA.-D-GLUCOPYRANOSYLOXY)-7-HYDROXY-6-METHOXY-

Systematic Name

English

FRAXETIN 8-.BETA.-D-GLUCOPYRANOSIDE

Common Name

English

FRAXETOL 8-GLUCOSIDE

Common Name

English

FRAXIN [MI]

Common Name

English

Code System Code Type Description

CAS

524-30-1